

February 10, 2023

Peter Wolfe  
Chief Financial Officer  
ZyVersa Therapeutics, Inc.  
2200 N. Commerce Parkway , Suite 208  
Weston , FL 33326

Therapeutics, Inc.  
Statement on Form S-1  
2023

Re: ZyVersa  
Registration  
Filed January 27,  
File No. 333-269442

Dear Peter Wolfe :

We have limited our review of your registration statement to those issues we have addressed in our comments. In some of our comments, we may ask you to provide us with information so we may better understand your disclosure.

Please respond to this letter by amending your registration statement and providing the requested information. If you do not believe our comments apply to your facts and circumstances or do not believe an amendment is appropriate, please tell us why in your response.

After reviewing any amendment to your registration statement and the information you provide in response to these comments, we may have additional comments.

Registration Statement on Form S-1 filed January 27, 2023

Cover Page

1. Please revise your heading on the cover page to also list the shares of common stock issuable upon the exercise of the warrants. In this regard, we note your statements throughout the prospectus that these underlying shares are also being registered pursuant to the registration statement.

2. We note that your placement agents will sell your common stock and accompanying warrants on a "best efforts" basis. Please revise the cover page to provide all information required by Item 501(b)(8)(ii) and (iii) of Regulation S-K. Also, please tell us how the following disclosure on the cover page, and similar disclosure on page 149, is consistent with a best-efforts offering: "The delivery of the shares of Common Stock, the pre-funded warrants and the warrants to purchasers is expected to be made on or about [ ], 2023." In

Peter Wolfe  
FirstName LastNamePeter  
ZyVersa Therapeutics, Inc.Wolfe  
Comapany10,  
February NameZyVersa  
2023 Therapeutics, Inc.

February  
Page 2 10, 2023 Page 2  
FirstName LastName

the event the offering will not remain open for an extended period of time, please clarify.

3. Please revise the cover page to clearly state that this is a best efforts offering with no minimum and that your placement agents may not sell the entire amount

of common stock

being offered.

4. We note your disclosure on the cover page that your offering of common shares and

accompanying warrants will be at an "assumed" combined public offering price. Please

tell us whether you plan to amend prior to effectiveness to include the final offering price

as opposed to an assumed offering price. Also, please revise your cover page to disclose

that the combined public offering price per share and accompanying warrant will be fixed

for the duration of this offering.

5. Please revise your cover page to highlight your intention to use approximately \$10.4

million of the net proceeds from your offering to redeem all of the PIPE Shares sold

immediately prior to the closing of the Business Combination at 120% of the issue price.

Please also explain, if true, that only net proceeds received in excess of this amount will

be available for working capital and other general corporate purposes.

In making your

revisions, state the difference between 1) the aggregate amount

received from the sale of

the PIPE Shares immediately prior to the closing date of the Business Combination, and 2)

the aggregate repurchase price of the PIPE shares.

Use of Proceeds, page 57

6. We note your intention to use approximately \$10.4 million of the net proceeds of the

offering to redeem all of the PIPE Shares. However, we also note that this is a best efforts

offering with no minimum offering amount. Please revise your

disclosure to explain how

proceeds will be allocated in the event you raise less than the full

\$10.4 million required to

redeem all PIPE Shares.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Liquidity and Capital Resources, page 119

7. Please revise your liquidity and capital resources discussion to note the following: 1) that

approximately 99% of the then-outstanding shares of Larkspur Class A common stock

redeemed their shares in connection with the Business Combination; (2)

the unlikelihood

that the company will receive significant proceeds from exercises of

the public warrants

because of the disparity between the exercise price and the current

trading price of the

Class A Common Stock; and (3) your intended use of \$10.4 million of

the offering

proceeds to redeem all of the PIPE shares. In addition, discuss the

effect of this offering

on the company's ability to raise additional capital.

Peter Wolfe

ZyVersa Therapeutics, Inc.

February 10, 2023

Page 3

PIPE Transactions and Related Agreements

PIPE Registration Rights Agreement, page 153

8. Your statement on page 153 that "this registration statement" was filed to cover the resale

of all the shares of common stock issuable upon conversion or exercise of the PIPE Shares

and the PIPE warrants is not consistent with the remainder of the

prospectus, which relates

to a primary best efforts offering. Please reconcile.

General

9. Where appropriate, revise the prospectus to discuss why you intend to exercise your right

to redeem the PIPE Shares and the associated risks such redemption may pose to other

shareholders given your liquidity and capital resources discussion. For

example, discuss

how the redemption of the PIPE Shares would impact the cash you have

available for

other purposes and to execute your business strategy, and how the repurchase of the PIPE

Shares could impact the market price of the company's common stock.

We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Refer to Rules 460 and 461 regarding requests for acceleration. Please allow adequate time for us to review any amendment prior to the requested effective date of the registration statement.

Please contact Lauren Hamill at 303-844-1008 or Laura Crotty at 202-551-7614 with any other questions.

FirstName LastNamePeter Wolfe  
Corporation Finance  
Comapany NameZyVersa Therapeutics, Inc.

Sciences  
February 10, 2023 Page 3  
cc: Jared Kelly  
FirstName LastName

Sincerely,  
Division of  
Office of Life